X

Hiran Orgochem Ltd Stock Analysis

Small Cap
Evaluated by 54 users | BSE: 506170 | NSE: |
Pharmaceuticals & Drugs
Mumbai based Hiran Orgochem was Incorporated in 1983 is a leading integrated manufacturer of active pharmaceutical ingredients and formulations. Since its incorporation, Hiran has focused on Manufacturing the Quinolones group of API's with its principal products comprising Ciprofloxacin,...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'06Mar'07Mar'08Mar'09Mar'10Jun'11Jun'12Jun'13Mar'14Mar'15
Return on Capital Employed 27.71%4.37%6.02%-3.73%7.3%-52.81%-9%-65.15%-12.6%-37.63%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 11510811918920311838.9243.50.4
Y-o-Y Gr. Rt.--5.9%9.9%58.4%7.6%-41.7%-67.1%-38.4%-85.3%-88.1%
Adjusted EPS (Rs.) 3.50.190.57-2.280.57-6.66-1.32-6.05-0.97-1.03
Y-o-Y Gr. Rt.--94.6%200%-500%NA-1268.4%NANANANA
Book Value per Share (Rs.) 12.1716.0116.6413.6114.913.353.28-2.78-4.68-6.32
Adjusted Net Profit 13.513-123-65.7-13-59.7-9.6-10.2
Net Op. Cash Flow (Rs. Cr.) -17.6-414.620.811.9-45.33.8-28.6-1.2-16.1
Debt to Cash Flow from Ops -1.86-1.1712.362.494.51-1.723.2-3.1-92.52-4.07
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Hiran Orgochem Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales -46.4%-71%-77.9%-88.1%
Adjusted EPS -187.3%-212.6%NANA
Book Value per Share -193-184.2-224.40
Share Price - - - -
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'06Mar'07Mar'08Mar'09Mar'10Jun'11Jun'12Jun'13Mar'14Mar'15
Return on Equity (%) 43.221.543.5-15.063.94-136.05-34.99-2278.6323.2721.04
Operating Profit Margin (%) 21.117.189.84-3.746.33-45.47-31.42-244.02-243.24-829.87
Net Profit Margin (%) 11.740.932.53-6.351.46-55.52-33.4-249.01-272.72-2416.22
Debt to Equity 0.70.570.650.720.692.332.75-3.24-2.48-1.05
Working Capital Days 1753544242662623468849065,42624,780
Cash Conversion Cycle 48120112472372-23-110-782-6,807
Entity Percentage Holding
Promoters 23.88%
Institutions 7.75%
Non-Institutions 68.37%
Pledged *66.3388.8388.8388.8490.6190.2189.7889.7889.7889.78
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Data is not available for this company.

Data is not available for this company

Mumbai based Hiran Orgochem was Incorporated in 1983 is a leading integrated manufacturer of active pharmaceutical ingredients and formulations. Since its incorporation, Hiran has focused on Manufacturing the Quinolones group of API's with its principal products comprising Ciprofloxacin, Ofloxacin, Levofloxacin, Enrofloxacin and now provides formulations as well.

Hiran today is the largest Ciprofloxacin, Ofloxacin, Levofloxacin and Enrofloxacin manufacturer in India and strives to attain

Mumbai based Hiran Orgochem was Incorporated in 1983 is a leading integrated manufacturer of active pharmaceutical ingredients and formulations. Since its incorporation, Hiran has focused on Manufacturing the Quinolones group of API's with its principal products comprising Ciprofloxacin, Ofloxacin, Levofloxacin, Enrofloxacin and now provides formulations as well.

Hiran today is the largest Ciprofloxacin, Ofloxacin, Levofloxacin and Enrofloxacin manufacturer in India and strives to attain Global Leadership. The Company has achieved this position due to its strong commitment and ability to deliver unparalleled excellence in customer service.  Hiran's Ability to provide services on a Quick-turn and cost-effective basis has resulted in successfully expanding its customer base and delivering solid operating returns.

The company is having presence in more than 56 Countries. Their Export percentage is about 40% - 45% of the total Sales Turnover. Currently we are working on approvals for US FDA, COS and TGA. 

Product range of the company includes:

API

  • Ciprofloxacin HCL / Base
  • Ciprofloxacin Lactate
  • Ciprofloxacin HCL Compacted
  • Ciprofloxacin HCL Micronised
  • Ofloxacin HCL / Base
  • Levofloxacin Hemihydrate
  • Quinine Sulphate
  • Quinine BiSulphate
  • Quinine HCL
  • Quinine DiHCL

Veterinary Products

  • Enrofloxacin Base / HCL / Lactate
  • Difloxacin Base / HCL / Lactate
  • Sarafloxacin Base / HCL / Lactate

Products under development

  • Azithromycin
  • Clarithromycin
  • Omeprazole
  • Pantoprazole Sodium
  • Levocetirizine
  • Danofloxacin Mesylate
  • Fluconazole
  • Losartan Potassium
  • Atorvastatin
  • Simvastatin
  • Sildenafil Citrate
  • Moxifloxacin
  • Gemifloxacin
  • Lomefloxacin
  • Gatifloxacin
  • Pefloxacin 
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback